President Donald Trump promised a coronavirus disease 2019 (COVID-19) vaccine by the end of the year; COVID-19 survivors report anxiety over reinfection; colleges release COVID-19 testing and quarantine data.
On the final night of the Republican National Convention, President Donald Trump promised that the nation would produce a vaccine against coronavirus disease 2019 (COVID-19) “before the end of the year, or maybe even sooner.” According to The New York Times’ transcript of his speech formally accepting his renomination for the presidency, he highlighted the progress made under Operation Warp Speed, the administration’s project accelerating the development of a vaccine, and noted that 3 vaccines are currently in the final stage of trials.
Amid news this week of confirmed cases of COVID-19 reinfection, STAT reported that some survivors of the disease are experiencing anxiety over the possibility that they could experience it again. Those interviewed in the STAT article reported symptoms of panic when venturing into grocery stores and other crowded places, and experts say that the shortness of breath and elevated heart rate resulting from anxiety may be exacerbated by the breathing difficulties that can linger after a bout with the virus.
Colleges with students returning to campus for the fall semester are releasing COVID-19 testing data and the percentage of quarantine rooms occupied, according to the Associated Press. For instance, the University of Virginia currently has 5% of its quarantine rooms filled, and James Madison University has around 10% of its quarantine and isolation beds occupied. Meanwhile, Governor Andrew Cuomo of New York has announced conditions under which colleges must switch to virtual learning for 2 weeks: an outbreak of at least 100 cases or 5% of its population.
Exploring the Potential of Machine Learning in Optimizing Respiratory Failure Treatment
August 9th 2025Machine learning holds promise for optimizing treatment strategies and potentially improving outcomes in respiratory failure but future research and development are necessary to fully realize its potential in clinical practice.
Read More
Preventing Respiratory Illness and Death Through Tighter Air Quality Standards
June 1st 2021On this episode of Managed Care Cast, a research scholar at the Marron Institute of Urban Management at New York University discusses the latest findings in the Health of the Air report, which was presented at the recent American Thoracic Society 2021 International Conference.
Listen
RSV's Impact on Heart Health Emphasizes Broader Risks, Vaccination Importance for Older Adults
July 23rd 2025Respiratory syncytial virus (RSV) poses a significant, often overlooked, risk for serious cardiovascular complications in older adults, underscoring the need for vaccination in this population regardless of their preexisting health conditions.
Read More
Depemokimab Reduces Exacerbations Regardless of Baseline Asthma Control
July 3rd 2025Depemokimab significantly reduces asthma exacerbations, benefiting patients regardless of their baseline asthma control levels. A biologics license application for depemokimab is currently being reviewed by the FDA.
Read More